Juno Therapeutics presents TRANSCEND NHL 001 trial data
Juno Therapeutics reported data from the TRANSCEND trial of JCAR017 in relapsed and refractory aggressive B cell non-Hodgkin lymphom. TRANSCEND NHL 001 is a dose-finding study of JCAR017, which is administered following fludarabine/cyclophosphamide lymphodepletion. June 17, 2017